|  |  |
| --- | --- |
| **CHARACTERISTICS** | |
| Morphology | Gram-positive, nonmotile, nonspore-forming, small, slender rods that occasionally are arranged in a V shape, groups, or independent colonies. |
| Disease | Bifidobacterium are normal human microbiome bacteria, but can cause disease in immunocompromised individuals. Intestinal microbiota dysbiosis. |
| Zoonosis | None reported. |

|  |  |
| --- | --- |
| **HEALTH HAZARDS** | |
| Host Range | Humans, pigs. |
| Modes of Transmission | Unknown. |
| Signs and Symptoms | Gas, bloating, diarrhea, blood infections. |
| Infectious Dose | Unknown. |
| Incubation Period | Unknown. |

|  |  |
| --- | --- |
| **MEDICAL PRECAUTIONS/TREATMENT** | |
| Prophylaxis | Used as a probiotic to treat IBD, Chrone’s, celiac disease, atopic dermatitis, allergies. |
| Vaccines | None available. |
| Treatment | penicillin, ampicillin, amoxicillin/clavulanic acid, piperacillin/tazobactam, imipenem, and clindamycin |
| Surveillance | Monitor for symptoms. Diagnosis can be confirmed by PCR. |
| MSU Requirements | Report any exposures. |

|  |  |
| --- | --- |
| **LABORATORY HAZARDS** | |
| Laboratory Acquired Infections (LAIs) | None have been reported. |
| Sources | Human intestinal tract, vagina, feces, pig feces. Cultures, frozen stocks, other samples described in IBC protocol. |

|  |  |
| --- | --- |
| **RISK GROUP & CONTAINMENT REQUIREMENTS** | |
| Risk Group 1 | Agents that are not associated with disease in healthy adult humans. |
| BSL1 | For all procedures involving suspected or known infectious specimen or cultures. |
| ABSL1 | For all procedures utilizing infected animals. |

|  |  |
| --- | --- |
| **VIABILITY** | |
| Disinfection | 0.5% sodium hypochlorite (1:10 bleach:water), 70% ethanol |
| Inactivation | moist heat (15 minutes at 121oC) and dry heat (1 hour at 160-170oC). |
| Survival Outside Host | Unknown. |

|  |  |
| --- | --- |
| **SUPPLEMENTAL REFERENCES** | |
| BMBL | <https://www.cdc.gov/labs/BMBL.html> |
| NIH Guidelines | <https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf> |
| NIH | <https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/> |

|  |  |
| --- | --- |
| **SPILL PROCEDURES** | |
| Small | Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill with absorbent material and add fresh 1:10 bleach:water. Allow 20 minutes (or as directed) of contact time. After 20 minutes, cleanup and dispose of materials. |
| Large | * Immediately notify all personnel in the lab and clear all personnel from the area. Remove any contaminated PPE/clothing and leave the lab. * Secure the area by locking doors, posting signage and guarding the area to keep people out of the space.   For assistance, contact MSU's Biosafety Officer (406-994-6733) or Safety and Risk Management (406-994-2711). |

|  |  |
| --- | --- |
| **EXPOSURE PROCEDURES** | |
| Mucous membrane | Flush eyes, mouth, or nose for 5 minutes at eyewash station. |
| Other Exposures | Wash area with soap and water for 5 minutes. |
| Reporting | Immediately report incident to supervisor, complete a [First Report of Injury](https://firstreportinjury.mus.edu/) form, and submit to Safety and Risk Management. |
| Medical Follow-up | **During business hours:**  Bridger Occupational Health 3400 Laramie Drive Weekdays 8am -6pm. Weekends 9am-5pm  406-577-7674  **After business hours:**  Bozeman Deaconess Hospital Emergency Room  915 Highland Blvd |

|  |  |
| --- | --- |
| **PERSONAL PROTECTIVE EQUIPMENT (PPE)** | |
| Minimum PPE Requirements | Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants |
| Additional Precautions | Additional PPE may be required depending on lab specific SOPs and IBC Protocol. |